Melanoma Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2025-2034)

The melanoma market was valued at USD 7.50 Billion in 2024 driven by rising melanoma cases and advancements in personalized medicine across 8 major markets. It is anticipated to grow at a CAGR of 11.80% during the forecast period of 2025-2034 and attain a market value of USD 22.88 Billion by 2034.

Melanoma Market Overview

Melanoma is a rapidly progressing form of skin cancer that originates from melanocytes, the cells responsible for producing pigment. The rising number of cases is leading to a greater need for accurate and effective treatment options. Advancements in immunotherapies and targeted therapies, paired with improved early detection and increasing FDA authorizations, are revolutionizing the treatments. These developments drive market expansion by encouraging investment in drug research and meeting rising needs for diverse as well as effective melanoma treatment options.

Melanoma Market Growth Drivers

Rising Prevalence of Melanoma Drives Market Growth

Rising rates of melanoma, especially in regions with high levels of UV exposure has led to a notable increase in the need for successful treatments. In the United States, approximately 97,610 new cases of invasive melanoma were detected in 2023, impacting 58,120 males and 39,490 females, resulting in 7,990 fatalities (5,420 males and 2,570 females). This high frequency has motivated pharmaceutical companies to come up with new and enhanced treatment choices, driving market growth due to the ongoing need for effective therapies.

Melanoma Market Trends

Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.

Advancements in Immunotherapy

Immunotherapy is more commonly utilized in melanoma treatments, aiming at destroying cancer cells with greater accuracy and safeguarding healthy tissue. This pattern drives market expansion by increasing demand for new treatments with reduced side effects, improving patient results, and boosting treatment acceptance.

Increased Focus on Early Diagnosis Set to Strengthen Melanoma Market Value

Enhanced screening techniques and increased awareness efforts result in early detection of melanoma, thus improving treatment outcomes. This trend contributes to market expansion by increasing the need for treatments in the early stages, promoting progress in diagnostics, and providing more choices for timely intervention.

Developments of Targeted Therapies Likely to Fuel Market Expansion

Targeted therapies concentrate on mutations that cause cancer, enhancing treatment effectiveness for melanoma. These developments support market expansion by promoting research and investment in specialized therapies, fulfilling the need for improved and individualized healthcare choices.

Rising FDA Approvals and Clinical Trials Boost the Melanoma Market

Increased funding for clinical trials and FDA approvals is leading to the introduction of novel treatments in the market. For instance, in February 2024, the FDA approved Amtagvi (lifileucel), the initial cellular therapy for unresectable or metastatic melanoma, created by Iovance Biotherapeutics. Amtagvi demonstrated a 31.5% success rate in experiments where patients' T-cells were modified to attack melanoma cells. This progress drives market expansion by increasing sophisticated treatment choices and encouraging innovation in melanoma treatments.

Melanoma Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Therapy:

• Immunotherapies
• Targeted Therapies
• Chemotherapy
• Radiation Therapy
• Others

Market Breakup by Melanoma Stage:

• Early-stage Melanoma
• Advanced-stage Melanoma
• Metastatic Melanoma

Market Breakup by Route of Administration:

• Oral
• Parenteral
• Others

Market Breakup by End User:

• Hospital
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

Market Breakup by Region:

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Melanoma Market Share

Market Segmentation Based on the Therapy Set to Witness Substantial Growth

The market is segmented into immunotherapies, targeted therapies, chemotherapy, radiation therapy, and others based on the therapy. Among these, chemotherapy is expected to dominate the market as it can destroy cancer cells and reduce damage to healthy tissues. The increasing progress in molecular biology and the rising need for personalized medicine are expected to strengthen the value of the market in the forecast period.

Melanoma Market Analysis by Region

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. Among these, the United States is expected to dominate the market due to the presence of key pharmaceutical companies and high healthcare spending. Strong research endeavors and government support for cancer research are contributing to market growth in the region.

Additionally, India also holds a substantial share because of increasing healthcare knowledge and advancements in medical facilities. The growing occurrence of prostate cancer and the rising utilization of advanced therapies are expected to continue driving market expansion in the nation.

Leading Players in the Melanoma Market

The key features of the market report include clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Pfizer Inc

Pfizer Inc. is a global biotechnology and pharmaceutical leader based in New York. The company provides Tafinlar in conjunction with Mekinist for treating melanoma, specifically for those with BRAF V600E or V600K mutation.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a global leader in immune-oncology research based in New York. The company offers various immunotherapy drugs like Opdivo (nivolumab), a PD-1 inhibitor that boosts the immune system's capacity to recognize and eradicate cancer cells.

Novartis AG

Novartis is a Swiss-based pharmaceutical leader. The company provides combination therapies such as Tafinlar (dabrafenib) with Mekinist for melanoma patients with genetic mutations.

Eli Lilly and Company

Eli Lilly & Co. was established in 1876 and headquartered in Indianapolis, Indiana. Their key portfolio includes products like immunotherapy drugs like CYRAMZA (ramucirumab), which treat different types of cancers including melanoma. This shows the company's desire to broaden the use of immunotherapy for rare cancers.

Other companies include Merck & Co. Inc., Moderna, Inc., F. Hoffmann-La Roche AG (Genentech), Amgen Inc., GSK plc, and Regeneron Pharmaceuticals Inc

Key Questions Answered in the Melanoma Market

• What was the melanoma market value in 2024?
• What is the melanoma market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is the market segmentation based on the therapy?
• What is the market breakup based on the melanoma stage?
• What is the market segmentation based on the route of administration?
• What is the market breakup based on the end user?
• What are the major factors aiding the melanoma market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major melanoma market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the melanoma market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• How effective is chemotherapy for melanoma patients?
• What treatments are commonly used for early-stage melanoma?
• What benefits do parenteral treatments provide in melanoma therapy?
• How do hospitals approach melanoma treatment?
• How is India’s melanoma market evolving with healthcare advancements?

More Insights On

Unresectable Melanoma Market

This product will be delivered within 3-5 business days.